About OcuMension
OcuMension is a company based in Shanghai (China) founded in 2017. The company has 489 employees as of December 31, 2024. OcuMension operates in a competitive market with competitors including Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
- Headquarter Shanghai, China
- Employees 489 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Ocumension Therapeutics
-
Annual Revenue
$58.26 M (USD)66.2as on Dec 31, 2024
-
Net Profit
-$37.45 M (USD)30.69as on Dec 31, 2024
-
EBITDA
-$30.41 M (USD)37.98as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
489
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of OcuMension
OcuMension is a publicly listed company on the HKEX with ticker symbol 1477 in Hong Kong, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of OcuMension
Unlock access to complete
Unlock access to complete
Funding Insights of OcuMension
Detailed funding history for OcuMension
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OcuMension
Investment portfolio details for OcuMension
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OcuMension
Detailed financials for OcuMension
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Ocumension Comparisons
Peer comparison for OcuMension
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OcuMension
OcuMension operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Annexon, Aldeyra, Nicox, Gyroscope and MeiraGTx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| Locked | Locked | Locked |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| Locked | Locked | Locked |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| Locked | Locked | Locked |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| Locked | Locked | Locked |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
|
| Locked | Locked | Locked |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized.
|
Detailed competitors of OcuMension
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Ocumension
Complete news archive for OcuMension
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OcuMension
OcuMension was founded in 2017.
OcuMension is headquartered in Shanghai, China.
As of Dec 31, 2024, the latest employee count at OcuMension is 489.
Annual revenue of OcuMension is $58.26M as on Dec 31, 2024.
Founded in 2017 and based in Shanghai, China, operations are focused on the ophthalmology sector. A platform for eye medicine development is maintained, with lead candidates including intravitreal implants for uveitis, nitric oxide-based treatments for glaucoma, and therapies for allergic conjunctivitis and macular degeneration. Additional pipeline items address postoperative inflammation, dry eye, blepharitis, ocular hypertension, bacterial infections, corneal rejection, and optic neuritis.
OcuMension's top competitors include Annexon, Alimera Sciences and MeiraGTx.
Yes, OcuMension is publicly traded on HKEX under the ticker symbol 1477.
The ticker symbol of OcuMension is 1477 on HKEX.